dBET6 is a highly cell penetrant, potent and selective BET (bromodomain and extra-terminal domain) degrader that induces rapid (<4hrs) degradation of BRD2, BRD3 and BRD4 and complete down-regulation of c-MYC protein and induction of apoptosis. dBET6 exhibits potent anti-cancer activities.
highly cell penetrant, potent and selective BETdegrader that induces rapid degradation of BRD2, BRD3 and BRD4
Proceedings of the National Academy of Sciences of the United States of America, 115(22), E5086-E5095 (2018-05-17)
Competitive BET bromodomain inhibitors (BBIs) targeting BET proteins (BRD2, BRD3, BRD4, and BRDT) show promising preclinical activities against brain cancers. However, the BET protein-dependent glioblastoma (GBM)-promoting transcriptional network remains elusive. Here, with mechanistic exploration of a next-generation chemical degrader of
Processive elongation of RNA Polymerase II from a proximal promoter paused state is a rate-limiting event in human gene control. A small number of regulatory factors influence transcription elongation on a global scale. Prior research using small-molecule BET bromodomain inhibitors
Nature chemical biology, 14(5), 431-441 (2018-03-28)
Dissection of complex biological systems requires target-specific control of the function or abundance of proteins. Genetic perturbations are limited by off-target effects, multicomponent complexity, and irreversibility. Most limiting is the requisite delay between modulation to experimental measurement. To enable the
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.